BAX — Baxter International Inc.

As of 2026-08-27, sentiment has shifted positive following the July 30 Q2 report: organic revenue grew 5% to $2.96B, adjusted EPS printed $0.56 versus $0.37 consensus, and full-year adjusted EPS guidance was raised to $1.95-$2.15. The stock rallied roughly 15-19% post-print, institutional accumulation has been noted, and put/call interest is low. The main counterweight is that Wall Street's average target (~$24.40) is now below the market price, so the easy multiple expansion may already be done.

Reported history is distorted by the Vantive/Kidney Care separation - revenue steps down from $3.885B in Q4 2023 to a re-based ~$2.5-$3.0B quarterly range - so the first part of the three-year window is not comparable. Using the re-based 2024-2026 trend, revenue is growing steadily: Q2 2026 revenue of $2.96B was +5.3% YoY, accelerating from +2.9% in Q1 2026 and +4.3% in Q2 2025. GAAP profitability is noisy: Q4 2025 had a -$1.128B net loss and a 19.4% gross margin, while Q2 2026 gross margin is 34.9% and operating margin is 7.3%. The real picture is a low-single-digit-growth med-tech franchise inflecting off a post-spinoff, charge-laden trough; the next few quarters will show whether that inflection is durable or just tariff-refund/Q2 one-off noise.

On trailing GAAP, BAX is unratable - PE TTM is -12.7x and EPS TTM is -$2.06 - because of impairments and one-time charges. On forward adjusted earnings, as of 2026-08-27 the stock trades at about 12.6x consensus next-FY EPS of $2.05, versus a 5-year average P/E of 20.45x. Price/sales of 1.17x is roughly 43% below the 5-year average of 2.05x. That is cheap versus its own history, but not an unambiguous bargain: the low multiple partially reflects $8.6B of long-term debt, negative TTM operating margin, and unresolved operational issues.

At $25.93, BAX is pricing in a successful but modest turn - not a disaster, not a boom. The market has already repriced the stock above the average analyst target ($24.40) after the Q2 beat, so the low-hanging fruit has been picked. From here, upside to $28-$30 requires H2 EPS to actually land at or above the $1.95-$2.15 guidance and for margins/FCF to improve; if pump remediation or tariffs create another Q4-style charge, the stock could fall back toward the low-$20s.

As of 2026-08-27, RSI(14) was 51.9, neutral. Price was 3.4% below the 20-day SMA, 7.8% above the 50-day SMA, and 28.9% above the 200-day SMA. This is consolidation within an uptrend: the rally off the 52-week low of $15.73 is intact, but short-term momentum has stalled below the $28-$30 zone. An investor looking to buy might prefer a reclaim of the 20-day (~$26.85) or a retest of the 50-day (~$24.05) rather than chasing.

• Tariffs: BAX got a one-time $75M refund in Q2, but management guides to a $40M net tariff drag in H2 2026; further trade-policy shifts could hit gross margins.
• Interest rates/balance sheet: with $8.6B long-term debt and a net-leverage target of 3.0x, higher-for-longer rates raise refinancing costs despite ongoing tender offers.
• Hospital capex/budgets: cash-strapped hospital systems are constraining capital-equipment demand, particularly in Healthcare Systems & Technologies.
• Regulatory/quality: Novum IQ LVP corrective actions and injectable supply constraints are limiting revenue and adding remediation costs.
• Healthcare demand/utilization: resilient hospital volumes and aging demographics support core consumables, offsetting some macro headwinds.

• Q3 2026 earnings expected late October 2026 - evidence of sustained organic growth and FCF inflection.
• New CFO John Rogers assumes the role October 1, 2026; potential capital-allocation updates or financial-transformation actions.
• Resolution of Novum IQ LVP corrective actions or easing of injectable supply shortages.
• Debt reduction / achieving the 3.0x net-leverage target; possible refinancing or credit upgrade.
• Additional tariff relief or refunds in the back half of 2026.

• Another large GAAP charge or impairment - both Q4 2024 and Q4 2025 produced operating losses and negative headline EPS.
• Underlying margin compression persists: management noted gross and operating margins were down in Q2 once the tariff refund is excluded.
• High leverage: debt-to-equity is 1.56 and long-term debt is $8.6B, while trailing free cash flow is thin. Last four reported quarters generated only ~$678M of FCF.
• Operational/regulatory failure to resolve pump remediation could hurt reputation, sales, and costs.
• The stock has outrun sell-side targets, so any disappointment in H2 execution could trigger a sharp momentum reversal.

BAX is a legitimate show-me turnaround: Q2 2026 revenue grew 5% organically, adjusted EPS beat handily, and guidance was raised. But with $8.6B of long-term debt, negative trailing GAAP EPS, weak FCF, and unresolved pump/supply issues, the risk/reward at $25.93 is balanced rather than compelling. It is a patient hold/watch candidate rather than a high-conviction buy right now.

Applied a 13.5x justified forward P/E to consensus next-FY EPS of $2.054. The 13.5x multiple is roughly a 34% discount to Baxter's 5-year average P/E of 20.45x, reflecting high leverage, low organic growth, and unresolved operational issues.